Affymetrix 437 Arrayer

Affymetrix 437 阵列仪

• 批准号: 6440784
• 负责人: Norma Jean Nowak
• 金额: $ 12.5万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6440784
• 关键词: biomedical equipment purchase; functional /structural genomics; gene expression; genome; high throughput technology; microarray technology

Advances in technology fostered through the Human Genome Program have made global comparative assessment of differences between genomes and their gene expression a reality. Funds are being requested for the purchase of the Affymetrix 437 arrayer in order to upgrade from our Affymetrix 417 arrayer. The 437 will provide several advantages over the prototype arrayer currently in use in the DNA Microarray and Genomics Resource, and will allow continued integration with our Affymetrix GeneChip reader, and Affymetrix 428 scanner. The demand for array fabrication has increased dramatically over the past year, and with the current arrayer we are facing a backlog. At present the Affymetrix oligonucleotide arrays are being used in a discovery mode to identify patterns of gene expression in certain cell types and tissues as well as to make highly quantitative comparisons in gene expression levels between paired samples. The new arrayer would provide greater through-put, efficiency, and speed to meet the rising demand from researchers to design their own custom arrays either using genes from our resource clone collection databases, or from a combination of these and GeneChip predictions. Researchers at RPCI and the School of Medicine and Biomedical Sciences at SUNY Buffalo are in a unique position, in that close collaboration with clinical personnel allows access to a wide variety of patient material and identification of many interesting and clinically relevant diseases and syndromes. The ability to define gene function/pathways in model systems as well as define molecular signatures for disease through differential genomic and gene expression analysis will greatly enhance ongoing research programs. The requested instrumentation will afford the DNA Microarray and Genomics Resource with the capacity to continue to provide high quality custom genomic and expression arrays.

人类基因组计划促进的技术进步使对基因组及其基因表达之间差异的全球比较评估成为现实。正在请求资金购买 Affymetrix 437 阵列器，以便从我们的 Affymetrix 417 阵列器升级。与目前 DNA 微阵列和基因组学资源中使用的原型点阵仪相比，437 具有多种优势，并且可以继续与我们的 Affymetrix GeneChip 阅读器和 Affymetrix 428 扫描仪集成。在过去的一年里，阵列制造的需求急剧增加，而目前的阵列机我们面临着订单积压的问题。目前，Affymetrix 寡核苷酸阵列正用于发现模式，以识别某些细胞类型和组织中的基因表达模式，并对配对样品之间的基因表达水平进行高度定量的比较。新的阵列仪将提供更高的吞吐量、效率和速度，以满足研究人员不断增长的需求，即使用我们的资源克隆收集数据库中的基因或将这些基因与 GeneChip 预测相结合来设计自己的定制阵列。 RPCI 和纽约州立大学布法罗分校医学与生物医学科学学院的研究人员处于独特的地位，因为与临床人员的密切合作可以获取各种患者材料并识别许多有趣的临床相关疾病和综合征。在模型系统中定义基因功能/通路以及通过差异基因组和基因表达分析定义疾病分子特征的能力将极大地增强正在进行的研究项目。所需的仪器将提供 DNA 微阵列和基因组资源，并能够继续提供高质量的定制基因组和表达阵列。